• Dr. Rohan Hockings re-appointed as Managing Director
• Prof. Ian Constable appointed as Non-Executive Director
• Dr. Michael Rosenblatt and Mr. Jason Haddock resign as Non-Executive Directors

PYC Therapeutics (ASX:PYC) has announced changes to its Board and Executive management team designed to support the Company's delivery of its near-term growth ambitions. Dr. Rohan Hockings has been re-appointed as Managing Director of the Company and will resume responsibility for progressing the Company's pipeline of drug candidates with disease-modifying potential through critical near-term human safety and efficacy read-outs. Prof. Ian Constable has been appointed as a Non-Executive Director of the Company to provide access to his deep knowledge of the clinical development, regulatory engagement, and commercialisation activities required in support of the development of novel therapeutics. Dr. Michael Rosenblatt and Mr. Jason Haddock have resigned from their roles as Non-Executive Directors of the Company. PYC will continue to build out both its Board and Executive management team over the coming months as it progresses its pipeline of drug candidates into late-stage clinical development. The Company is preparing for a period of substantial growth, and these changes will support the progression of multiple concurrent clinical development programs.

PYC Therapeutics is preparing for a period of substantial growth as the Company progresses multiple drug candidates with disease-modifying potential into late-stage clinical development.